Hansoh Pharma Inks $1.5B Deal to License QX004N Anti-IL-23p19 Monoclonal Antibody from QuanX Biotech for China
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
Qyuns
Developer of Biologics for Autoimmune and Allergic Diseases
▎WuXi AppTec Content Team Report
Just now,HansohHansoh Pharma Announces Signing of Licensing Agreement with Quanxin BiotechHansoh Pharma will obtain the exclusive license from Quanxin Biotech to develop and commercialize in China (including Hong Kong, Macao, and Taiwan regions).QX004N Monoclonal Antibody。
According to the agreement, Hansoh Pharma will be responsible for the research, development, production, and commercialization of all developable dosage forms and indications of QX004N in China, and will make payments.RMB 75 millionRMB Down Payment andNo more than 1.032 billion yuanPotential payments for RMB's research and development, regulatory milestones, and sales-based commercialization milestones, as well as tiered royalties based on future product sales.
Quanxin Biotech Focuses on Developing Biological Therapies for Autoimmune and Allergic Diseases. The Company Officially Listed on the Hong Kong Stock Exchange in March This Year.ListedQX004N is a product in Quanxin Bio's R&D pipeline.IL-23p19 Inhibitor. By binding to the p19 subunit of IL-23, this product blocks the interaction between IL-23 and IL-23R as well as the corresponding signal transduction, thereby inhibiting the development of Th17 cells and leading to a reduction in the production of IL-17 cytokines.
According to the announcement, QX004N is an innovative candidate drug applicable for psoriasis and Crohn's disease.The product has initiated multiple clinical studies, with the highest stage of development in China being Phase 2 clinical trials.
This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Feel free to share it on your personal social media feed. For authorization to repost, please contact us via a message on the "MedView" WeChat official account.For other collaboration needs, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biomedicine and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.
